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Abstract 
Multiple sclerosis (MS) patients treated with natalizumab often face the uncommon 
but severe complication of developing progressive multifocal leukoencephalopathy (PML). 
PML may be further complicated by immune reconstitution inflammatory syndrome (IRIS) 
after the removal of the drug. Since both PML and IRIS are associated with high morbidity and 
mortality rates, early clinical and radiological diagnosis of these complications is of paramount 
importance. Here, we report a case of an adult male patient who was diagnosed with PML after 
receiving natalizumab therapy for 6 years for the treatment of MS. Upon cessation of natalizumab, 
he presented with a paradoxical worsening of clinical and radiological findings consistent with 
an inflammatory brain injury due to IRIS. He was treated with high dose corticosteroid therapy 
followed by a gradual improvement in clinical and imaging findings. This article illustrates the 
magnetic resonance imaging (MRI) features of natalizumab‑associated PML‑IRIS, along with a 
brief overview of its clinical features, complications and management strategies. 
Keywords: magnetic resonance imaging, natalizumab, multiple sclerosis, progressive multifocal 
leukoencephalopathy, immune reconstitution inflammatory syndrome
Introduction
Natalizumab is a monoclonal antibody used 
to treat relapsing multiple sclerosis (MS). Its 
mode of action is to produce a blockage of an 
integrin adhesion molecule, thereby preventing 
white blood cells from crossing the blood-
brain barrier and restricting the inflammatory 
response. It is administered intravenously 
once every 4 weeks (dose: 300 mg) in adult 
patients with relapsing MS in whom it is known 
to substantially decrease disease activity 
and prevent disease progression. However, 
its therapeutic efficacy has to be weighed 
against a serious associated side effect: the 
likelihood of developing progressive multifocal 
leukoencephalopathy (PML). PML is an 
opportunistic infection of the brain parenchyma 
caused by the JC virus and is known to show high 
morbidity and mortality rates (1–7).
Case Report
An adult male patient (aged 40 years) was 
being treated at our hospital (1) for relapsing 
MS since 1998. He had been on natalizumab 
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therapy for 6 years until being diagnosed with 
PML in April 2014, after which natalizumab 
was discontinued. Magnetic resonance imaging 
(MRI) of the brain in April 2014 showed a large, 
poorly marginated, T2 hyperintense lesion 
involving the left middle cerebellar peduncle 
(MCP) and left cerebellar hemisphere (Figure 1). 
Figure 1: An axial T2W MRI of the brain at the 
level of the ponto-medullary junction 
(April 2014 study) shows a large, 
poorly-marginated, T2 hyperintense 
PML lesion involving the left MCP 
and left cerebellar hemisphere.
This lesion did not show post-contrast 
enhancement (Figure 2). 
The imaging features were typical of PML. 
The patient then underwent three sessions 
of plasmapheresis followed by a brief clinical 
response. He again presented in June 2014 with 
progressively increasing unsteadiness and left 
facial hypoaesthesia. A clinical examination 
showed left cerebellar dysfunction and left 
trigeminal nerve involvement. A cerebrospinal 
fluid (CSF) study showed elevated levels of 
protein (609 mg/dL) and IgG (34.7 mg/dL) 
without pleocytosis. A polymerase chain reaction 
(PCR) test for the JC virus (JCV) DNA was 
positive. The subsequent MRI on June 2014 
showed an interval increase in the size of the 
previous PML lesion and an interval appearance 
of post-contrast enhancement along the margins 
of the lesion (Figures 3 and 4), which was not 
seen in the April 2014 MRI. Imaging findings 
confirmed the clinical diagnosis of PML-
associated immune reconstitution inflammatory 
syndrome (IRIS) occurring due to the suspension 
of natalizumab therapy. 
Figure 2: Contrast-enhanced axial T1W MRI 
at the level of the MCP (April 
2014 study) shows no evidence of 
enhancement in the PML lesion.
Figure 3: Coronal double inversion recovery 
image at the level of the ventricular 
trigones (June 2014 study) shows a 
slight interval increase in the size of 
the PML lesion since the previous 
April 2014 study. Typical small 
ovoid hyperintense MS plaques are 
noted in the right periventricular 
region.
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Figure 4: Contrast-enhanced axial T1W MRI 
at the level of the MCP (June 2014 
study) shows an interval appearance 
of gadolinium enhancement at 
the margins of the PML lesion in 
keeping with IRIS.
The patient was subsequently treated over 
one week with intravenous methylprednisolone. 
A follow-up MRI after 6 weeks showed a 
decrease in the size and a decrease in the 
previously noted contrast enhancement of the 
PML-IRIS lesion. The patient showed parallel 
clinical improvement. He is presently on oral 
maintenance steroid therapy.
Discussion
After the first 2–3 years of treatment with 
natalizumab, the PML incidence increases with 
increased duration of drug exposure. Patients 
develop symptoms approximately 17–25 months 
after treatment (3,4). The approximate risk of 
developing PML in MS patients treated with 
natalizumab is about 3–4/1000 (4). Cumulative 
increased exposure to natalizumab increases the 
risk of developing PML. The risk is significantly 
higher in patients who have previously 
received immunosuppressive treatments or in 
combination with natalizumab. In our patient, 
the delayed appearance of PML after 6 years may 
be explained by the fact that he was not treated 
with other immunosuppressants. Reports in the 
literature also mention a low viral load and high 
anti-JCV antibody titre as possible causes for 
decreased susceptibility to PML (5,6).
The presenting symptoms of PML in 
MS patients include progressive clinical 
deterioration, changes in cognition and 
personality, aphasia, hemiparesis, seizures 
and visual disturbances. The pathological 
hallmark of PML is a progressive demyelination 
of oligodendrocytes without a significant 
inflammatory response. Its clinical diagnosis 
is aided by a MRI evaluation and the detection 
of JCV DNA on CSF analysis. Early diagnosis of 
PML is crucial because a delay in the diagnosis 
has a negative impact on the overall prognosis 
(1–8).
An awareness of the MRI features of PML 
is of paramount importance. The common 
sites for the development of PML lesions are 
the supratentorial subcortical white matter, 
with occasional involvement of the deep grey 
matter. The brainstem and cerebellum are often 
involved; however, spinal cord involvement is 
rare. The MRI diagnosis of PML in patients with 
MS and the decision of whether a new lesion is 
MS or PML is challenging, especially as it affects 
therapy. Characteristic MRI features of PML 
in MS include large, diffuse and asymmetric 
(> 3 cm), unifocal or multifocal, subcortical 
white matter lesions (affecting “U” fibres) that 
are hyperintense on T2W and FLAIR sequences 
and hypointense on T1W sequences. The lesions 
typically show a well-marginated border towards 
the grey matter and a poorly-marginated border 
towards the white matter. On the other hand, 
MS lesions are smaller, typically ovoid or flame-
shaped, commonly seen in the periventricular 
white matter, often seen in the spinal cord, may 
show restricted diffusion, have mild mass effect 
and have a ring-like enhancement in the acute/
active phase. PML lesions typically do not show 
mass effect. PML is characterised histologically 
by paucity of inflammation and hence, 
contrast-enhancement is uncommon (4–11). 
PML linked to natalizumab treatment 
is associated with 20% mortality rates with 
survivors sustaining moderate to severe 
disabilities. It is treated by the immediate 
discontinuation of the drug and often, 
plasmapheresis is performed to rapidly remove 
the drug from the circulation. Adjuvant 
immunomodulatory therapy with mefloquine 
and mirtazapine has been reported to show 
favourable responses (1–11).
Unfortunately, as in our patient, the 
sudden removal of natalizumab or the use of 
plasmapheresis may lead to the development of 
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IRIS, which is defined as a paradoxical clinical 
and radiographic worsening after a period of 
stability. PML-IRIS typically presents with 
a worsening of earlier PML symptoms; this 
occurs a few days to weeks after natalizumab 
discontinuation or the start of plasmapheresis. 
Immune reconstitution is characterised by 
intense perivascular CD4 lymphocytic infiltration 
and inflammatory brain damage. IRIS is 
associated with mortality rates of 20–30%. 
Important MRI features of PML-IRIS include the 
development of new inflammatory changes with 
an increase in PML lesion size. There may be an 
interval appearance of contrast-enhancement, 
oedema and mass effect. PML-IRIS has also been 
described in HIV-positive patients being treated 
by highly active antiretroviral therapy, in which 
case, infection and lymphoma are likely imaging 
differentials for PML-IRIS lesions. However, a 
correlation between the clinical scenario of MS 
post-natalizumab therapy and the typical MRI 
findings of PML lesions showing enhancements 
clinches the IRIS diagnosis. PML-IRIS can lead 
to substantial long-term sequelae with more 
extensive necrotic tissue damage than just the 
JCV infection with severe residual parenchymal 
and cortical atrophy (4–11).
Corticosteroid therapy in high doses, which 
is usually intravenous methylprednisolone 
(1 g per day) for 5 days, is the recommended 
treatment for PML-IRIS. This is followed by oral 
steroids with tapered doses. Prednisolone in a 
dose of 0.75 mg/kg has been suggested by some 
authors as an acceptable taper dose for some 
forms of IRIS (12). IRIS can persist for several 
months and hence, long-term steroid therapy 
may be necessary along with close clinical and 
MRI monitoring (2,3). Favourable responses 
to treatment are associated with a gradual 
regression of the acute inflammatory features on 
MRI (8). 
In conclusion, diagnosing natalizumab-
associated PML-IRIS is of paramount 
importance. It requires regular clinical follow-
up and vigilance, reliable JCV PCR testing and 
well-defined MRI criteria for the recognition of 
PML-IRIS. Optimised treatment strategies of 
IRIS reactions and the development of robust 
predictive markers for patients at risk for PML 
must be sought. Clinicians and radiologists 
must work in close collaboration to avoid 
a misdiagnosis of these potentially lethal 
conditions.
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